ALZN - Alzamend Neuro, Inc.
1.14
0 0%
Share volume: 698
Last Updated: Wed 05 Feb 2025 12:00:04 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
14.20%
PREVIOUS CLOSE
CHG
CHG%
$1.14
0.00
0.00%
Fundamental analysis
26%
Profitability
18%
Dept financing
43%
Liquidity
32%
Performance
30%
Performance
5 Days
0.44%
1 Month
-10.24%
3 Months
-30.49%
6 Months
-55.12%
1 Year
31.19%
2 Year
-88.82%
Key data
Stock price
$1.14
DAY RANGE
$1.14 - $1.14
52 WEEK RANGE
$0.37 - $15.06
52 WEEK CHANGE
$29.08
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Stephan Jackman
Region: US
Website: alzamend.com
Employees: 4
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alzamend.com
Employees: 4
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Recent news